HUVECs serve as a valuable model for researching vascular endothelium features and key biological pathways related to endothelial function22. They are frequently utilized in in vitro research because they are easily isolated from the human umbilical cord, readily available, and their behavior is well-documented 22. Figure 4 shows an example of the morphology of HUVECs and the umbilical cord that was dissected to isolate HUVECs. In addition, HUVECs have the capacity to accurately represent the human vascular endothelium. This is consistent with the results of Lau et al.23, who evaluated HUVECs and human umbilical artery endothelial cells (HUAEC) as in vitro models for cardiovascular research. Their study showed that both cell types displayed comparable features in terms of cell viability, metabolic activity, and membrane integrity, indicating that both cell types are equally appropriate for cardiovascular research. HUVECs are commonly used to investigate angiogenesis in vitro and its associated disorders24. Many studies have utilized HUVECs to explore the molecular processes related to blood vessel formation, such as endothelial cell migration, growth, and branching25.

Moreover, HUVECs are a useful model for researching vascular illnesses such as atherosclerosis, thrombosis, and endothelial dysfunction26. In earlier studies, they were utilized to replicate disease conditions in a laboratory setting to explore the fundamental mechanisms involved in vascular pathology. The HUVEC model is valuable for studying how hemodynamic forces affect the endothelium and the development of atherosclerotic plaques. This model enables researchers to subject endothelial cells to shear stress under controlled flow conditions, replicating blood flow conditions in living organisms22. The HUVEC model has proven valuable for investigating various biological processes and disorders, including inflammation, apoptosis, preeclampsia, cardiovascular diseases, and regenerative medicine22, 27.

Nevertheless, one of the primary limitations of HUVECs is their unsuitability for long-term investigations22. HUVECs typically have a lifespan of around 10 passages, although some researchers suggest that these cells may lose their original features and responsiveness to stimuli after passage 622. HUVECs may not be suitable for vascularizing specific tissues, such as neurological tissue, which requires a tightly sealed endothelium and an effective blood-brain barrier28, 29. Furthermore, as the human umbilical cord is fetal rather than maternal tissue, the fetal gender must be considered, as it might yield different results in metabolite levels and oxidative stress29. While HUVECs are commonly used in vascular biology research due to their ease of isolation and culture, they may not fully represent the phenotypic response of adult-derived endothelial cells30. This is because HUVECs are fetal cells and may not accurately reflect the characteristics and behavior of endothelial cells found in adult tissues. These limitations highlight the need to consider the specific requirements of each application when choosing endothelial cell types for research.

HAECs are commonly derived from the inner lining of the aorta, a major artery responsible for transporting oxygen-rich blood from the heart to the body. These cells can be sourced from various segments of the aorta, such as the ascending aorta (proximal to the heart) or the descending aorta (distal from the heart)31. The specific site of HAEC isolation may vary based on the research methodology or experimental design. HAECs are typically procured from explants of healthy human heart donors through surgical procedures or post-mortem tissue donations32. Samples containing the aortic endothelial layer are harvested, and endothelial cells are extracted and cultured in laboratory settings for further analysis and experimentation32. The collection and utilization of human tissue samples for research purposes are governed by ethical guidelines and regulatory approvals33.

HAECs offer an excellent model system for investigating various aspects of cardiovascular function and disease, such as atherosclerosis and endothelial dysfunction caused by different stressors34, 35. HAECs can be employed to evaluate changes in the vascular endothelium and its function at a preclinical stage, which holds potential for refining therapeutic strategies. In addition, HAECs have been found to exhibit robust angiogenic potential in 3D microfluidic angiogenesis systems, which is critical for investigating vessel formation and regeneration36. It was also reported that HAECs exhibit similar cellular characteristics to HUVECs in a 2D culture system37. The study of HAECs in laboratory settings has significantly contributed to our understanding of endothelial physiology and the pathogenesis of vascular diseases.

While in vitro cell cultures provide insight into the interactions of endothelial cells with diverse mediators, it is essential to acknowledge their inherent limitations, particularly regarding the uncertainty of translatability to human physiological contexts. Like other endothelial cell types, HAECs may undergo alterations upon extraction from their native human environments. This is primarily due to the absence of the intricate intercellular communications observed within the living organism, which cannot be fully captured via in vitro assays38. Furthermore, HAECs demonstrate variability according to factors such as donor age, health status, and genetic background, which could influence the consistency and reliability of research outcomes32. In contrast to utilizing immortalized endothelial cell lines or cells from more accessible sources like the human umbilical vein, isolating, culturing, and maintaining primary HAECs necessitate a more complicated and expensive process involving the acquisition of human heart donors through surgical procedures or post-mortem tissue donations32.

HCAECs are considered a dynamic organ exhibiting secretory, metabolic, and immune functions beyond their main role in modulating nutrient translocation across the vascular wall. HCAECs are specifically involved in the secretion of various vasoactive substances that regulate vascular smooth muscle tone and blood flow within the coronary arteries39. HCAECs originate from the coronary arteries of the human heart40, and they can be obtained from individuals undergoing percutaneous coronary interventions (PCI)41. Notably, most studies employ commercially available HCAECs purchased from authorized companies, such as Promocell (Germany) or Lonza (USA)42, 43. As indicated by these providers, primary HCAECs can be isolated not only from the main coronary arteries but also from their respective branches, including the right and left coronary artery, anterior descending, and circumflex branches, from a single donor. As these cells originate from human coronary arteries, they play a pivotal role in supplying oxygenated blood to the heart muscle and therefore are ideally suited for investigating the pathogenesis of coronary heart disease and developing innovative therapies39. Moreover, according to Lakota et al.43, HCAECs exhibit unique sensitivities and responses compared to endothelial cells derived from other vascular beds, as HCAECs were shown to have sensitivity to tumor necrosis factor alpha (TNFα)-induced expression of adhesion molecules compared to HUVECs and human dermal microvascular endothelial cells (HMVECs).

However, the considerable heterogeneity and organ-specific characteristics of HCAECs pose challenges in result interpretation and study reproducibility. This means that HCAECs might not be fully representative of the behavior of endothelial cells from other vascular beds, potentially resulting in inconclusive or inaccurate findings44. A study by Wagner et al.45 also emphasized that HCAECs were the only cells expressing spike protein post-SARS-CoV-2 infection, indicating distinct responses compared to other endothelial cells, such as HUVECs, HMECs, and human pulmonary arterial cells. This suggests that observations in HCAECs may not fully capture the responses of endothelial cells from diverse vascular beds or under varying pathological conditions. Besides that, the variability among donors can also affect the behavior and reactivity of HCAECs in vitro. Donor-related factors, such as age, sex, genetic background, and health status, may influence angiogenic responses, contributing to variability in experimental results46, 47. Obtaining HCAEC samples can be intricate, involving procurement from patient donors or acquisition from authorized companies with legal consent, potentially incurring higher costs41, 43.

HSV have been previously utilized in ex vivo assays. These veins are located beneath the skin and contain valves that prevent blood backflow, playing a crucial role in transporting deoxygenated blood from the leg to the heart51. Interestingly, HSVs are widely employed as a conduit for coronary artery bypass grafting52. According to the literature, HSVs have been extensively utilized in ex vivo tissue culture investigations, particularly for modeling intimal hyperplasia and exploring the causes of vein graft failure in coronary artery bypass grafting (CABG)53. In the context of angiogenesis research, as indicated in Table 3, most researchers have cultured saphenous veins by embedding them in a gel to observe sprouting formation. Conversely, there is limited specific mention of ex vivo tissue cultures in previous angiogenesis studies that used other veins, including the human umbilical vein.

The human arterial ring assay is an innovative system for the 3D study of angiogenesis. Arterial explants for ex vivo angiogenesis studies can be obtained from various sources, such as aortic tissue, choroid, epididymis, and skeletal muscle. Aortic explants are able to form branching microvessels when embedded in an extracellular matrix58. Table 4 shows a list of previous reports that utilized human artery explants in ex vivo angiogenesis studies.

Table 4

Artery explants	Angiogenesis-related study	Methods	References
Umbilical cord	Human tumor angiogenesis	- Human arterial rings assay. - Arterial rings were placed on 48-well cell culture dishes pre-coated with 100 µl of basement membrane extract (BME) and overlaid with 100 µl of BME. - Maximum growth velocity achieved at 14 days.	59
Umbilical cord	Kisspeptin-10 roles inhibiting angiogenesis in human blood vessels	- Vessels were cut into 1 mm sections. - The vessel ring was embedded in Matrigel (200 µl) and were cultured for 2-3 days with media consisting of 10% FBS.	60
Temporal artery biopsy	Giant cell arteritis	- Cultured in Matrigel for 5 days in 96 well plate.	61
Human umbilical cord	Identification of new genes regulating sprouting, screening pro and anti-angiogenic drugs, biomarkers and analysis of tumor microenvironmental effects on vessel formation	- Artery was cut into 30 1-2 mm sections and placed inside a 48-well plate that was precoated with 100 µl of BME gel. - Cultured for 18 days with media consisting of 5% FBS.	62
Human Mesenteric arteries	Age-associated deterioration in angiogenesis, blood flow and glucose homeostasis by therapeutically targeting CD47	- Arterial ring assay by cutting the vessel into 1 mm sections. - Embedded with Matrigel with cell media. - Incubated the tissue for 15 days.	63

Abbreviation: BME: basement membrane extract; FBS: Fetal bovine serum

Excess angiogenesis also contributes to the pathogenesis of various ocular illnesses, including diabetic retinopathy, age-related macular degeneration (AMD), and retinopathy of prematurity64. Table 5 shows the usage of human retinal tissues used to investigate retina-related angiogenesis illnesses. Based on our literature search, there are only a small number of previous reports that used human retinal explants in angiogenesis studies. This might be due to the difficulty in obtaining donor eyes and the high level of competence required for retina manipulation, which may not be feasible with small samples65.

Table 5

Retina explant	Methods	References
Choroidal tissues	- Human choroidal explants were cultured in normal medium for 5 days for neovessel growth and undergo treatment.	64
Human iris	- Whole iris fragments were cut into 3 mm diameter segments and embedded with Matrigel in a 24-well plate. - The tissue explants were cultured with ECGM for 48 hours.	66
Choroidal explant	- Choroidal sprouting assay was conducted by embedding the samples with Matrigel in 24 well plate. - The samples were incubated for 1 day and continued with treatment. - The sprout image was captured at day 5.	67
Human retinal explants	- Each of the tissue explant was cut in to 4 mm diameter segments. - Then, the tissues were placed on top of a gel matrix. - The tissues were observed from day 2 to day 15.	68

Abbreviation: ECGM: Endothelial Cell Growth Medium

Clinical trials and research have led to the development of various effective anti-angiogenic treatments, such as bevacizumab, tyrosine kinase inhibitors like sorafenib, and human recombinant endostatin. These advancements indicate the potential of targeting angiogenesis for therapeutic purposes, particularly in the context of cancer diseases69. In addition, numerous clinical trials have assessed the safety and efficacy of VEGF therapy for ischemic coronary and peripheral arterial disease (Table 6), which showed potential therapeutic benefits despite the low significance. The findings from human models in angiogenesis assays have significant implications for clinical practice, particularly in the development of therapeutic strategies for various diseases. By utilizing human-derived models, researchers can gain insights that are more directly applicable to patient care.

Angiogenesis assays have become significant tools in the discovery of anti-angiogenic drugs for cancer treatment. Identification of vascular endothelial growth factor (VEGF) as an important regulator of angiogenesis led to the development of bevacizumab (Avastin), which is a monoclonal antibody that suppresses VEGF70. Preclinical studies of angiogenesis with human endothelial cells revealed that bevacizumab was capable of inhibiting tumor angiogenesis, thereby supporting its clinical use. Clinical trials have shown that bevacizumab, when used together with chemotherapy, enhances outcomes for several malignancies, including osteosarcoma70. The successful translation of angiogenesis testing results into the clinic underlines the value of these models in developing effective therapies for cancer patients. Aside from cancer treatment, angiogenic therapies have also been used in clinical trials for retinal and ischemic diseases. Table 6 shows previous studies that conducted clinical trials associated with angiogenic agent targets.

Table 6

Angiogenic therapy target	Study design (Disease; Time; Drugs; Dose; Number of patients; Phase)	Outcomes	References
VEGFR inhibitor	Advanced renal cell cancer; Axitinib + pembrolizumab; 5mg + 2 mg/kg; 6 weeks; n = 52; Phase 1b	The treatment combination of axitinib + pembrolizumab is tolerable and shows promising antitumour activity in patients with treatment-naive advanced renal cell carcinoma No unexpected toxicities were observed 94% of patients experienced some degree of tumour shrinkage.	71
VEGF	Osteosarcoma; 29 weeks; Bevacizumab + MAP; 15 mg/kg; n = 3; Phase II	4-year EFS rate: 57.5% ± 10.0% Overall survival rate: 83.4% ± 7.8% 28%evaluable patients had good histologic response (<5% viable tumor) to preoperative chemotherapy.	70
VEGF inhibitor	Branch retinal vein occlusion; 12 months; dexamethasone & ranibizumab; 0.7 mg (dexamethasone) & 0.5 mg (ranibizumab); n = 307	Dexamethasone and ranibizumab improved best-corrected visual acuity and anatomical outcomes. Dexamethasone did not show non-interiority to ranibizumab Dexamethasone associated with increased risk of intraocular pressure elevation and cataract pressure	72
VEGF	Angina; 0,3 and 12 months; AdVEGF-DΔNΔC (AdVEGF-D) or placebo (control) groups; 200 µL at 10 sites; n = 30	Shown significant increase in myocardial perfusion at 3 months and 12 months compared to baseline.	73
VEGFR inhibitor	Hepatocellular carcinoma; 4 weeks; oral dovitinib; 500 mg (5 days on & 2 days off); n = 24; phase II	Overall response rate was 48%, including 13% complete remission Time to progression: 16.8 months Overall survival: 34.8 months	74
BMSC	Critical limb ischemia; over 12 months; stempeucel®; 2 million cells/kg body weigh; n = 24; Phase III	Showed statistically significant reduction in rest pain and ulcer size (healing of ulcer) as compared to baseline. Increased the blood flow to the ischemic limbs as ABPI and ASP increased.	75

Abbreviations: VEGFR: Vascular Endothelial Growth Factor Receptors; VEGF: Vascular Endothelial Growth Factor; MAP: methotrexate, doxorubicin, cisplatin; EFS: event-free survival; AdVEGF-DΔNΔC: Adenoviral intramyocardial VEGF-D; BMSC: Bone marrow-derived mesenchymal stromal cells; ABPI: Ankle–brachial pressure index; ASP: Ankle systolic pressure

Angiogenesis denotes the intricate process of forming new blood vessels, a pivotal aspect of human physiological functions. Utilizing human models in studying angiogenesis yields significant outcomes for diseases associated with this process. Nonetheless, the study of angiogenesis through human models is not devoid of limitations due to various factors. Firstly, ethical constraints emerge as a prominent issue. The ethical framework governing research involving human subjects underscores fundamental principles, including respect for individuals and associated responsibilities mandated by justice, whereas regulations concerning research involving animal subjects primarily focus on limited considerations of welfare76. Other than that, human samples can show inherent individual variability in terms of genetic differences, health conditions, and age-related factors. These factors might add complexity and variability to the study outcomes65. Obtaining human tissue samples for angiogenesis assays can also pose challenges, particularly when considering specific tissues or disease conditions, resulting in limitations in sample size and study replication65. Working with human samples also involves high costs due to various factors, including sample collection, processing, and storage77. Due to the limited availability of human samples from donors, most researchers are forced to purchase samples from a small number of established companies, such as Promocell (Germany) or Lonza (USA)42. All these limitations and issues must be carefully considered by researchers before embarking on their angiogenesis-related research.

Currently, the development of human model technologies in the angiogenesis research field has shown potential for enhancing our understanding and for developing new therapeutics. Models such as organ-on-a-chip systems, 3D bioprinted tissues, and ex vivo culture have the potential to overcome the limitations of conventional in vitro and in vivo assays by offering more accurate and physiologically relevant platforms for studying angiogenesis. As these technologies evolve, they can enhance the precision of drug testing. For example, organ-on-a-chip systems allow for the precise control of the cellular microenvironment6. By incorporating human endothelial cells and other supporting cell types, organ-on-a-chip devices can be used to study angiogenesis in the context of specific organ systems, such as the brain, heart, or kidney6. These models can provide valuable insights into the role of angiogenesis in organ development, homeostasis, and disease pathogenesis. 3D bioprinting technology also allows for the precise deposition of cells, biomaterials, and growth factors to create complex, tissue-like structures. By incorporating human endothelial cells and supporting cell types into 3D bioprinted constructs, researchers can develop highly customizable angiogenesis assays that mimic the native extracellular matrix and cellular microenvironment78. Additionally, CRISPR can be used to create patient-derived induced pluripotent stem cells (iPSCs) with disease-relevant genetic mutations, which can then be differentiated into endothelial cells and used to develop personalized angiogenesis assays24. As these emerging technologies continue to advance, they will likely play an increasingly important role in angiogenesis research. By providing more accurate and physiologically relevant human models, researchers will be better equipped to study the complex mechanisms of angiogenesis, identify novel therapeutic targets, and develop more effective treatments for angiogenesis-related diseases.

It is important to understand the development of the vascular system and the mechanisms that lead to vascular diseases in order to discover new, effective treatments. Combining in vitro and ex vivo models using human samples offers a comprehensive approach to studying angiogenesis. This integrative strategy bridges the gap between simplified in vitro systems and the complex realities of in vivo conditions, enhancing the translational potential of research findings. However, key challenges remain, including ethical considerations, variability in human samples, difficulties in tissue sample acquisition, and the cost of obtaining samples. Addressing these challenges is critical for advancing the field. Therefore, collaboration with ethical boards and regulatory agencies to establish clear, standardized guidelines for the use of human tissues in angiogenesis research can help streamline the approval process and ensure that research is conducted in a manner that respects donor rights. By utilizing large-scale biobanks that store a wide variety of human tissue samples, researchers can select samples that best match their study criteria and reduce variability65. In addition, establishing collaborative networks between research institutions, hospitals, and biobanks can improve access to human tissue samples and facilitate the sharing of resources and information. Additionally, funding from government agencies, non-profit organizations, or private-sector partnerships can encourage sharing of expensive resources, such as specialized equipment or reagents, through collaborative agreements or shared facilities. All these measures might help reduce the overall cost burden for individual research groups. By addressing these limitations through strategic collaboration, future researchers can enhance the effectiveness of human models in angiogenesis assays, ultimately leading to more accurate and clinically relevant findings.

ABPI: Ankle-brachial pressure index; AKT: Ak strain transforming (Protein kinase B); ASP: Ankle systolic pressure; ATP: Adenosine triphosphate; BMSC: Bone marrow-derived stem cell; BrdU: Bromodeoxyuridine; CABG: Coronary artery bypass grafting; CAD: Coronary artery disease; ECM: Extracellular matrix; EFS: Event free survival; ETT: Exercise treadmill tests; FGFs: Fibroblast growth factors; HAECs: Human aortic endothelial cells; HCAECs: Human Coronary Artery Endothelial Cells; HMVEC: Human Microvascular Endothelial cells; HSV: Human saphenous veins; HUVECs: Human umbilical cord vein endothelial cells; MMPs: Matrix metalloproteinases; MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide; NCD: Non-communicable diseases; OOAC: The organ-on-a-chip; PDGF: Platelet-derived growth factor; PFS: Progression-free survival; PI3K: Phosphoinositide 3-kinases; TGFβ: Transforming growth factor beta; VEGF: Vascular Endothelial Growth Factor

We would like to appreciation to the financial support provided by the Ministry of Higher Education (MOHE), Malaysia through the Fundamental Research Grand Scheme (FRGS), under grant number FRGS/1/2023/SKK06/UKM/02/16.

Maisarah was the primary author and was responsible for drafting and editing the manuscript. Nur Najmi, Azizah, and Nadiah provided supervision, critical review, and contributed to manuscript revisions. Mohd Faizal, Safa, and Ishamuddin participated in the review process and provided feedback on the manuscript. All authors read and approved the final version of the manuscript.

Fundamental Research Grand Scheme (FRGS), under grant number FRGS/1/2023/SKK06/UKM/02/16.

Data and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Not applicable.

Not applicable.

The authors declare that they have no competing interests.